## **Unaudited Financial Statements**

for the Year Ended 31st March 2017

for

DRUGLAB118 LTD

# Contents of the Financial Statements for the Year Ended 31st March 2017

	Page
Company Information	1
Abridged Balance Sheet	2
Notes to the Financial Statements	4
Accountants' Report	5

## DRUGLAB118 LTD

## Company Information for the Year Ended 31st March 2017

**DIRECTORS:** Ms K C Bergman

S I Grossman C Lyon

**REGISTERED OFFICE:** 43 Coniscliffe Road

Darlington Co. Durham DL3 7EH

**REGISTERED NUMBER:** 08447515 (England and Wales)

ACCOUNTANTS: Mitchell Gordon LLP

43 Coniscliffe Road

Darlington Co. Durham DL3 7EH

# Abridged Balance Sheet 31st March 2017

	31/3/17	31/3/16
	£	£
CURRENT ASSETS		
Debtors	317	582
Cash at bank and in hand	845	656
	1.162	1,238
CREDITORS		
Amounts falling due within one year	167,012	138,613
NET CURRENT LIABILITIES	(165,850)	(137,375)
TOTAL ASSETS LESS CURRENT		
LIABILITIES	(165,850)	(137,375)
CAPITAL AND RESERVES		
Called up share capital	100	100
Retained earnings	(165,950)	(137,475)
SHAREHOLDERS' FUNDS	(165,850)	(137,375)

Page 2 continued...

## Abridged Balance Sheet - continued 31st March 2017

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st March 2017.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st March 2017 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
  - preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections
- (b) 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

All the members have consented to the preparation of an abridged Income Statement and an abridged Balance Sheet for the year ended 31st March 2017 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors on 21st December 2017 and were signed on its behalf by:

C Lyon - Director

## Notes to the Financial Statements for the Year Ended 31st March 2017

### 1. STATUTORY INFORMATION

Druglab118 Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

### 2. ACCOUNTING POLICIES

### Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements have been prepared on the going concern basis of accounting. At the balance sheet date the company's liabilities exceeded its assets by £165,850. Included within liabilities is an amount of £14,788 owed to the company director. The company director has confirmed that repayment of the loan will not be sought if it proved to be prejudicial to the company.

#### Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

### **Taxation**

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

### Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

### 3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1.

### Accountants' Report to the Board of Directors on the Unaudited Financial Statements of Druglab118 Ltd

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Abridged Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Druglab118 Ltd for the year ended 31st March 2017 which comprise the Abridged Income Statement, Abridged Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at http://www.accaglobal.com/rulebook.

This report is made solely to the Board of Directors of Druglab118 Ltd, as a body, in accordance with the terms of our engagement letter dated 19th August 2015. Our work has been undertaken solely to prepare for your approval the financial statements of Druglab118 Ltd and state those matters that we have agreed to state to the Board of Directors of Druglab118 Ltd, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/factsheet163. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Druglab118 Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Druglab118 Ltd. You consider that Druglab118 Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Druglab118 Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Mitchell Gordon LLP 43 Coniscliffe Road Darlington Co. Durham DL3 7EH

21st December 2017

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.